Dr. Holger Zimmermann
AiCuris Anti-infective Cures GmbH
Before becoming CEO of AiCuris in 2015, Holger worked for two years as the company’s Managing Director and Deputy CEO and also six years as Chief Scientific Officer. He was head of virology and project leader for the HCMV-portfolio and was part of the team which successfully led the licensing of these promising products to Merck & Co (MSD) in 2012, one of the largest agreements of its kind in the European biotech industry. Holger was part of the spin-out from the infectious disease unit of Bayer HealthCare which formed AiCuris in 2006.
Prior to AiCuris, Holger worked at Bayer HealthCare as Laboratory head and Project leader in virology. He obtained his PhD in biology at the University of Cologne and worked for seven years at various academic institutions, including three years at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore.
Holger is author/co-author of numerous scientific publications and named inventor on more than 25 patent applications. He is a member of national and international scientific societies and serves on several boards including: The International Society on Antiviral Research, The German Society of Virology (GfV) on Antiviral Therapy, and BIO Deutschland (Executive Board).